Background: Conventionally the detection of hepatitis B virus (HBV) DNA is carried out on serum using commercial or in house PCR assays. Oral fluid obtained by use of commercial collection devices offers several advantages compared to venepuncture: it is non invasive, painless, safe and less expensive.
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Methods: Seventy-three HBV DNA positive and 74 HBV DNA negative paired serum/oral fluid samples, drawn from patients visiting university hospitals, were analysed. The detection of HBV DNA in oral fluid was carried out through an optimised nested PCR with a 95% detection limit of 457 copies/ml
Results: A clinical sensitivity and specificity of 69.9% (95%CI: 58.6%-79.2%) and 100% (95%CI: 95.1%-100.0%) respectively was achieved. A statistically significant association was found between the serum HBV DNA viral load and the detection of HBV DNA in oral fluid (p < 0.001). In samples with a minimum concentration of 10 5 copies/ml (high viraemia), it was possible to detect the virus in oral fluid in 91.8% (95%CI:80.8%-96.8%) of the cases. A concentration of 10 5 copies/ml being considered as the minimum level needed for the transmission of HBV via needlestick or mucosal scratch, the optimised nested PCR could be used in epidemiological surveys for mapping of active replicating carriers.
Conclusion: An optimised nested PCR for HBV detection, with a 95% detection limit of 457 copies/ml and a sensitivity of 91.8% in patients with a minimum serum concentration of 10 5 copies/ml, was developed. The use of serum remains the golden standard for individual diagnosis, monitoring of antiviral treatment or detection of occult infections. However, oral fluid sampling by oracol collection device offers through all its advantages versus venepuncture a good alternative in epidemiological and surveillance surveys. The haemagglutinin (HA) and neuramidase (NA) genes are considered to be responsible for the major part of the antigenic variability of influenza A viruses. Reportedly, specific amino acid changes might even serve as molecular markers for the pandemic potential of avian influenza isolates.
We recently developed an Alignment & Mutation Analysis tool as an extension library for the BioNumerics software. Here, we illustrate the use of this versatile and powerful tool with publicly available sequences and trace files. The latter were automatically assembled into contigs and imported with the batch assembly plugin. Optimized settings for trimming and assembly minimized manual editing. Strain information was parsed along with the import and all data were stored in a single relational database.
Using this plugin, we were able to assemble 22,000 influenza A genome sequence trace files from the NCBI Trace Archive (http://0-ww.ncbi.nlm.nih.gov.catalog.llu.edu/ Traces/trace.cgi) in less than 30 minutes. For the HA and NA gene sequences of influenza A virus serotype H5N1, a multiple alignment was created and the nucleic acid sequences were translated into amino acids. Mutations were searched relative to a consensus sequence, which made ''hot spots'' for mutations to become immediately apparent. For each mutation, its position, type (silent, missense, indel), nucleotide change and amino acid change was listed. When browsing through the mutation list, the cursor jumps automatically to the corresponding position on the alignment and curves, allowing the researcher to visually evaluate the mutation in its context.
Overall, performing the complete mutation analysis within a single software package offers much added flexibility, in comparison with online analysis tools. 
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Reliable and fast assays are prerequisite for rapidly identifying infectious agents such as emerging viruses, zoonotically transmitted or otherwise rare and unusual viruses in order to take appropriate epidemiologic actions and/or to choose the best treatment. However, detection and identification of viruses without specific knowledge about their genome can be challenging.
We developed an assay that combines virus capsid preparation with generic PCR. The first step is the physical and biochemical purification of a given sample by targeted digestion of contaminating host nucleic acids. This is followed by a degenerate oligonucleotide primer (DOP) PCR. The primer population is optimized for the detection of virus-sized genomes. Products can be identified by cloning and sequencing or by subjecting the PCR products to high throughput sequencing. Various DNA viruses (including HSV, VZV, SV40, AAV, EBV, parvoviruses and hepatitis B) and RNA viruses (including HTLV-1 and HTLV-2, several animal retroviruses, poliovirus, hepatitis A, a human corona virus, human metapneumovirus and influenza virus) were detected in cell cultures and clinical samples.
This novel technique requires no prior sequence information to amplify viral genomes, but nonetheless be able to amplify at least a portion of each viral genome. It can detect viruses in a variety of samples using only one aliquot of the sample per assay. These features render it ideal for virus discovery and detection of virus in samples for which other methods have failed. The ability of the DOP to detect all viruses, human and zoonotic, in parallel, is also a useful asset in the context of emerging infectious diseases, which often are of zoonotic origin. Another application is the identification of viral agents in immuno-compromised patients, who often suffer from unusual infections. Moreover, generic detection of viral agents maybe useful in assuring the safety of regulated products such as cell culture based vaccines. Molecular biology has become an integral part of the diagnosis of infectious diseases. Recently, quantitative real-time PCR (QPCR) methods have been developed for the diagnosis of a wide range of infectious diseases. The use of QPCR as a tool for diagnostic virological and viral research laboratories has greatly increased in recent years. It often replaces conventional PCR and amplicon detection systems which are more complex and laborious, with a higher risk of amplicon carry-over contamination.
The new QPCR methods presented here utilize broadly targeted primers and probes for rational and sensitive detection and quantification of variable RNA viruses. They take advantage of the dual properties, both RNA and DNA dependent DNA polymerase activities, of the rTth thermostable polymerase, and thermolabile UNG with dUTP to protect against inadvertent contamination of samples with amplimers.
Specimen collection and delivery to the laboratory without delay and with minimal losses are vital components for reliable RNA measurements in a diagnostic service. 62 Cerebrospinal fluid, 71 stool specimens & 203 human nasopharyngeal aspirates involved in this study.
We describe broadly targeted QPCRs which use several alternative conserved sequences. The assays developed will be useful tools for performing infection surveys. The development of broadly reactive QPCRs assays for RNA viruses was challenging due to the extensive genetic diversity among the different viruses. The assays in the present study were able to detect all or most of the intended target viruses in less than 3 hours, to achieve the ideals broad targeting, high sensitivity, high specificity and quantitative results.
The technologies described in this study have common features. They are a platform for further development of diagnostic tools for screening and detection of viruses in known viral diseases, maybe also for discovering new viruses. Single-stranded DNA fragments attain a number of conformational forms which may be separated by electrophoresis in native polyacrylamide gels giving a characteristic pattern of electrophoretic bands. Minute sequence changes (e.g. point mutations) may have significant effect on electrophoretic pattern of single-stranded DNA. Changes of gel temperature during electrophoresis increase the sensitivity of mutation detection in PCR products; this technique, a modification of SSCP technique, was named MSSCP (where M stands for ''multitemperature''). This method modified in our laboratories was applied for characterization of influenza A cDNA fragments. A series of primers were synthesized after the comparison of the hemagglutinin, neuraminidase and PB2 gene sequences of different origin. PCR reactions were run using these primers and the products were denatured. Single-stranded DNA fragments were subjected to MSSCP electrophoresis where, after silver staining, they gave characteristic ssDNA band patterns. This technique was applied to analyse hemagglutinin, neuraminidase and PB2 gene fragments from recent isolates of avian flu. Minor differences within a serotype were detected which makes the MSSCP technique a valuable tool for quick preliminary characterization of influenza variants. Two commercial enzyme immunoassay kits: Ridascreen Norovirus (3rd generation, R-Biopharm AG, Germany) and Denka Seiken NV-AD (II) (Denka Seiken Co. Ltd., Tokyo, Japan), that detect norovirus antigen in human stool specimens, were evaluated to access whether they can be used in routine diagnosis and outbreak investigation. A total number of 154 stool specimens collected from young children from primary schools who suffered from acute gastroenteritis were tested for norovirus antigen by the two ELISA kits and by Real Time-PCR method. The Ridascreen kit revealed a high sensitivity of 90.8%, a specificity of 95.5%, and an efficiency of 95.2%. The Denka ELISA kit had a sensitivity of 72.3%, a specificity of 82.9%, and an efficiency of 87.0%. The precision for Ridascreen is 1.6% for positive control whereas it is 7.7% for Denka kit. These findings indicate these ELISA kits may be used as alternative methods for screening of norovirus in stool specimens. doi:10.1016/j.ijid.2008.05.1340 
